The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Commentary|Articles|August 14, 2026
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
Author(s)Sagar Lonial, MD, Jonah Feldman
Fact checked by: Sabrina Serani, Kelly King
Sagar Lonial, MD, provides commentary on the key questions raised by recent data on lenalidomide maintenance for patients with newly-diagnosed multiple myeloma.
Advertisement
Advertisement
For years, questions have lingered about the trade-off of delaying disease progression vs additional toxicity with prolonged maintenance therapy in multiple myeloma, but it has been difficult to confirm whether patients could discontinue maintenance, and when it was safest to do so.
Related to this article
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
Advertisement
Advertisement